Drugs / MAVATREP
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01631487 | Jul 2012 → Mar 2013 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01454245 | Jul 2011 → Apr 2012 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01343303 | Mar → Dec 2011 | osteoarthritis, knee | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT00933582 | Aug 2009 → Jun 2010 | osteoarthritis, knee | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 1 | NCT01006304 | Jun 2009 → Jun 2010 | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MAVATREP | ChEMBL registry synonym — accepted as the source's own label CHEMBL2364618 ↗ |
| Known as | JNJ-39439335 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01343303 ↗ |
| Action | Inhibit | “JNJ-39439335 (a TRPV1 Antagonist)” NCT01006304 ↗ |
| Modality | Small molecule | — CHEMBL2364618 ↗ |
| Route | Oral | “a single oral dose (50 mg) of JNJ-39439335” NCT00933582 ↗ |
| Target | TRPV1 | “JNJ-39439335 (a TRPV1 Antagonist)” NCT01006304 ↗ |